The benefits and harms of breast cancer screening: an independent review

The breast cancer screening programmes in the United Kingdom currently invite women aged 50-70 years for screening mammography every 3 years. Since the time the screening programmes were established, there has been debate, at times sharply polarised, over the magnitude of their benefit and harm, and...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	British journal of cancer Ročník 108; číslo 11; s. 2205 - 2240
Hlavní autoři:	MARMOT, M. G, ALTMAN, D. G, CAMERON, D. A, DEWAR, J. A, THOMPSON, S. G, WILCOX, M
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Basingstoke Nature Publishing Group 11.06.2013
Témata:	Aged Biological and medical sciences Breast cancer Breast Neoplasms - diagnosis Breast Neoplasms - mortality Breast Neoplasms - prevention & control Diagnostic Errors Early Detection of Cancer - adverse effects Early Detection of Cancer - methods Early Detection of Cancer - statistics & numerical data Evidence-Based Medicine Female Gynecology. Andrology. Obstetrics Humans Mammary gland diseases Medical sciences Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Randomized Controlled Trials as Topic Risk Assessment Tumors United Kingdom - epidemiology United Kingdom > UK Mammary gland diseases Breast disease Cancerology Breast cancer Malignant tumor Review Medical screening Bibliographic review Cancer
ISSN:	0007-0920, 1532-1827, 1532-1827
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	The breast cancer screening programmes in the United Kingdom currently invite women aged 50-70 years for screening mammography every 3 years. Since the time the screening programmes were established, there has been debate, at times sharply polarised, over the magnitude of their benefit and harm, and the balance between them. The expected major benefit is reduction in mortality from breast cancer. The major harm is overdiagnosis and its consequences; overdiagnosis refers to the detection of cancers on screening, which would not have become clinically apparent in the woman's lifetime in the absence of screening. Professor Sir Mike Richards, National Cancer Director, England, and Dr Harpal Kumar, Chief Executive Officer of Cancer Research UK, asked Professor Sir Michael Marmot to convene and chair an independent panel to review the evidence on benefits and harms of breast screening in the context of the UK breast screening programmes. The panel, authors of this report, reviewed the extensive literature and heard testimony from experts in the field who were the main contributors to the debate. 85 references
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 ObjectType-Article-2 ObjectType-Feature-1
ISSN:	0007-0920 1532-1827 1532-1827
DOI:	10.1038/bjc.2013.177